Jefferies maintains Genzyme at buy

Genzyme Corp. was maintained by Jefferies & Co., Inc. analyst Adam K. Walsh at a buy rating as the company prerecorded fourth-quarter 2005 revenue of $722 million, 3% under the analyst's estimate of $744 million. Earnings per share for the same quarter are estimated at $0.63. Shares of the Cambridge, Mass., biopharmaceutical company were down 62 cents, or 0.83%, at $74.42 on volume of 3,418,544 shares versus the three-month running average of 2,145,650 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.